Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.

ABSTRACT:

Purpose

To compare the clinical remission and survival between CLAG and FLAG induction chemotherapy in treating patients with refractory or relapsed acute myeloid leukemia (R/R AML).

Methods

103 R/R AML patients were consecutively enrolled in this prospective cohort study. 55 patients were treated by CLAG induction chemotherapy as follows: 5 mg/m²/day cladribine (days 1-5); 2 g/m²/day cytarabine (days 1-5) and 300 μg/day filgrastim (days 0-5). While 48 patients were treated by FLAG: 30 mg/m²/day fludarabine (days 1-5), 2 g/m²/day cytarabine (days 1-5), and 300 μg/day filgrastim (days 0-5).

Results

CLAG induction chemotherapy achieved 61.7% complete remission rate (CR) and 78.7% overall remission rate (ORR), which was similar

SUBMITTER: Bao Y 

PROVIDER: S-EPMC5996008 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature